It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

medicine

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
U.K. issues anaphylaxis warning on Pfizer vaccine after adverse reactions

World / Science & Health Dec 10, 2020

U.K. issues anaphylaxis warning on Pfizer vaccine after adverse reactions

Britain began mass vaccinating its population on Tuesday, part of a global drive that poses one of the biggest logistical challenges in peacetime history.

China’s state-backed coronavirus vaccine has 86% efficacy, says UAE

World / Science & Health Dec 9, 2020

China’s state-backed coronavirus vaccine has 86% efficacy, says UAE

China’s state-backed coronavirus vaccine protected 86% of people from getting COVID-19 in trials conducted in the United Arab Emirates, reported media outlets including Reuters, citing the UAE’s health ministry. The vaccine, developed by Sinopharm unit China National Biotec Group Co., has been granted emergency use ...

The pandemic public-debt dilemma

Commentary / World Dec 9, 2020

The pandemic public-debt dilemma

by Michael Spence and Danny Leipziger

Extraordinary times call for extraordinary measures. Failing bold action, developing countries could be on track to lose years or even decades of progress in the post-pandemic world.

How to vaccinate a nation of skeptics against COVID-19

Commentary / World Dec 9, 2020

How to vaccinate a nation of skeptics against COVID-19

by Lionel Laurent

How to convince people to actually take the shot. Achieving herd immunity may mean at least 80% of people will need the vaccine.

Testing times: More work needed on AstraZeneca/Oxford vaccine trials

World / Science & Health Dec 9, 2020

Testing times: More work needed on AstraZeneca/Oxford vaccine trials

by Kate Kelland

A Lancet study gave few extra clues about why efficacy was 62% for trial participants given two full doses, but 90% for a smaller subgroup given a half, then a full dose.

With Pfizer's COVID-19 shot, Britain prepares for world-first vaccine rollout

World Dec 6, 2020

With Pfizer's COVID-19 shot, Britain prepares for world-first vaccine rollout

Britain gave emergency use approval for the vaccine last week — jumping ahead in the global race to begin the most crucial mass inoculation program in history.

COVID-19: Nobody is safe until everyone is safe

Commentary / World Dec 4, 2020

COVID-19: Nobody is safe until everyone is safe

by Keizo Takemi and Achim Steiner

A recent study projected that unequal global distribution of COVID-19 vaccines could cost the world economy up to $1.2 trillion.

Language and lockdowns amid the pandemic

Commentary / World Dec 2, 2020

Language and lockdowns amid the pandemic

by Kaushik Basu

Reducing the issue to a binary question (Should we lock down or not?), or even a linear one (How much should we lock down?), oversimplifies a complicated problem.

A triumph of German innovation and immigration

Commentary / World Dec 1, 2020

A triumph of German innovation and immigration

by Hans-werner Sinn

The great advantage of BioNTech's approach is that it allows for the production of more than one billion vaccine doses within the space of just a few months.

Moderna to seek U.S. and EU clearance for COVID-19 vaccine

World Nov 30, 2020

Moderna to seek U.S. and EU clearance for COVID-19 vaccine

by Robert Langreth

The move came after a new analysis showed the vaccine was highly effective in preventing COVID-19 with no serious safety problems.

COVID-19 drugs from Lilly and Regeneron raise access and timing concerns

World / Science & Health Nov 29, 2020

COVID-19 drugs from Lilly and Regeneron raise access and timing concerns

Powerful drugs recently authorized by the U.S. that may prevent those at the earliest stages of COVID-19 from suffering severe disease present thorny new challenges, including who will get them and where they’ll be administered. Antibody treatments, like one from Regeneron Pharmaceuticals Inc. that was ...

Ratio of medical staff gives Japan edge against COVID-19, OECD says

National / Science & Health Nov 27, 2020

Ratio of medical staff gives Japan edge against COVID-19, OECD says

by Osamu Tsukimori

The nation is also helped by its better infrastructure, higher numbers of intensive care beds and higher government spending as a proportion of GDP.

« 1 … 6 7 8 … 122 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times